NeuroOne Medical Technologies Corporation
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-2.0M | $-2.4M | $-1.4M | $-1.6M | $-1.5M | $-2.3M | $1.8M | $-3.4M |
| Depreciation & Amortization | $47.0K | $60.0K | $65.5K | $64.3K | $66.6K | $65.6K | $65.1K | $64.1K |
| Depreciation | $41.4K | $54.5K | $59.9K | $58.7K | $61.0K | $60.1K | $59.5K | $58.5K |
| Amortization | $5.6K | $5.6K | $5.6K | $5.6K | $5.6K | $5.6K | $5.6K | $5.6K |
| Stock-Based Compensation | $352.8K | $342.1K | $359.3K | $358.6K | $316.7K | $250.2K | $339.2K | $340.4K |
| Net Cash from Operating Activities | $-1.1M | $-1.3M | $-3.1M | $-1.5M | $-1.5M | $-56.1K | $208.0K | $-2.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $19.7K | $38.5K | $40.8K | $10.6K | $43.5K | $3.2K | $24.4K | $36.9K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-19.7K | $-38.5K | $-40.8K | $-10.6K | $-43.5K | $-3.2K | $-24.4K | $-36.9K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $345.0K | $609.6K | $147.8K | $67.0K | $8.2M | $245.2K | $-509.3K | $2.5M |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | $-1.1M | $-1.4M | $-3.2M | $-1.5M | $-1.5M | $-59.3K | $183.6K | $-2.7M |